Newsfiscal.ai
TransCode Therapeutics Retains Tungsten Advisors for Strategic Review
· Published
Article summary
TransCode Therapeutics has engaged Tungsten Advisors to lead a formal strategic process aimed at maximizing the value of its lead therapeutic candidate, TTX-MC138, and its broader oncology portfolio.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…